Analyzing Xenetic Biosciences (NASDAQ:XBIO) & MOTIF BIO PLC/S (NASDAQ:MTFB)

Xenetic Biosciences (NASDAQ:XBIO) and MOTIF BIO PLC/S (NASDAQ:MTFB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, risk and valuation.

Earnings and Valuation

This table compares Xenetic Biosciences and MOTIF BIO PLC/S’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Xenetic Biosciences $20,000.00 280.52 -$12.77 million N/A N/A
MOTIF BIO PLC/S N/A N/A -$13.98 million N/A N/A

Xenetic Biosciences has higher revenue and earnings than MOTIF BIO PLC/S.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Xenetic Biosciences and MOTIF BIO PLC/S, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xenetic Biosciences 0 0 2 0 3.00

Xenetic Biosciences presently has a consensus price target of $2.25, suggesting a potential upside of 152.50%. Given Xenetic Biosciences’ higher possible upside, equities research analysts plainly believe Xenetic Biosciences is more favorable than MOTIF BIO PLC/S.

Institutional & Insider Ownership

3.2% of Xenetic Biosciences shares are held by institutional investors. 6.2% of Xenetic Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.


This table compares Xenetic Biosciences and MOTIF BIO PLC/S’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Xenetic Biosciences N/A -28.67% -22.85%


Xenetic Biosciences beats MOTIF BIO PLC/S on 6 of the 8 factors compared between the two stocks.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.


Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.

Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with's FREE daily email newsletter.